alt Hacker News> Imnsho this paper is very low quality
Compared to like a phase 3 clinical trial, sure. Compared to your average paper, and especially your average business paper I don't think that's the case.
> Imnsho this paper is very low quality
Compared to like a phase 3 clinical trial, sure. Compared to your average paper, and especially your average business paper I don't think that's the case.
I think there is some room in between those two.
At a minimum you'd expect a few more companies, more sources than just code review and code productivity metrics (this alone disqualifies the study because it centers on just one task: software development) etc.